A prospective cohort conversion study of twice-daily to once-daily extended-release tacrolimus: Role of ethnicity

Transplantation Research

Volumn 3, Issue 1, 2014, Pages

  Glick, Lauren ^a   Shamy, Fernanda ^b   Nash, Michelle ^b   Sokwala, Ahmed ^c   Malavade, Tushar ^c   Prasad, GV R ^d   Zaltzman, Jeffrey S ^d  

^a Keenan Summer Student Research Program St Michael's   (Canada)

^b Transplant Program St Michael's   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; ASIAN; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE COMPARISON; ETHNIC DIFFERENCE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 84907908122     PISSN: None     EISSN: 20471440     Source Type: Journal    
DOI: 10.1186/2047-1440-3-7     Document Type: Article

References (17)

1. Alloway R, Steinberg S, Khalil K, Gourishanker S, Miller J, Norman D, Hariharan S, Pirsch J, Matas A, Zaltzman J, Wisemandle K, Fitzsimmons W, First MR. Two years postconversion from a Prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients. Transplantation 2007, 83:1648-1651.
2. Ho ET, Wong G, Craig JC, Chapman JR. Once-daily extended-release versus twice-daily standard-release tacrolimus in kidney transplant recipients: a systematic review. Transplantation 2013, 95:1120-1128.
3. Hougardy JM, de Jonge H, Kuypers D, Abramowicz D. The once-daily formulation of tacrolimus: a step forward in kidney transplantation?. Transplantation 2012, 93:241-243.
4. Fanous H, Zheng R, Campbell C, Huang M, Nash M, Rapi L, Zaltzman JS, Prasad GVR. A comparison of the extended-release and standard-release formulations of tacrolimus in de novo kidney transplant recipients: a 12-month outcome study. Clin Kidney J 2013, 6:45-49. 10.1093/ckj/sfs169, 3560378, 23372940.
5. Prasad GV, Zaltzman JS, Huang M. Renal transplantation among South Asians: a North American perspective. Transplantation 2005, 79:855.
6. Prasad GV, Vangala SK, Silver SA, Wong SC, Huang M, Rapi L, Nash MM, Zaltzman JS. South Asian ethnicity as a risk factor for major adverse cardiovascular events after renal transplantation. Clin J Am Soc Nephrol 2011, 6:204-211. 10.2215/CJN.03100410, 3022244, 20884776.
7. Min SI, Ha J, Kang HG, Ahn S, Park T, Park D, Kim SM, Hong HJ, Min SK, Ha IS, Kim SJ. Conversion of twice-daily tacrolimus to once-daily tacrolimus formulation in stable pediatric kidney transplant recipients: pharmacokinetics and efficacy. Am J Transplant 2013, 13:2191-2197. 10.1111/ajt.12274, 23734831.
8. de Jonge H, Kuypers DR, Verbeke K, Vanrenterghem Y. Reduced C0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation. Transplantation 2010, 90:523-529.
9. Niioka T, Satoh S, Kagaya H, Numakura K, Inoue T, Saito M, Narita S, Tsuchiya N, Habuchi T, Miura M. Comparison of pharmacokinetics and pharmacogenetics of once-and twice-daily tacrolimus in the early stage after renal transplantation. Transplantation 2012, 94:1013-1019.
10. Glowacki F, Lionet A, Hammelin JP, Labalette M, Provot F, Hazzan M, Broly F, Noel C, Cauffiez C. Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on the pharmacokinetics of the prolonged-release, once-daily formulation of tacrolimus in stable renal transplant recipients. Clin Pharmacokinet 2011, 50:451-459. 10.2165/11587050-000000000-00000, 21528942.
11. Ro H, Min S-I, Yang J, Moon KC, Kim YS, Kim SJ, Ahn C, Ha J. Impact of tacrolimus intraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation. Ther Drug Monit 2012, 34:680-685. 10.1097/FTD.0b013e3182731809, 23149441.
12. Slatinska J, Rohal T, Wohlfahrtova M, Viklicky O. Long-term follow-up of stable kidney transplant recipients after conversion from tacrolimus twice daily immediate release to tacrolimus once-daily prolonged release: a large single-center experience. Transplant Proc 2013, 45:1491-1496. 10.1016/j.transproceed.2012.11.017, 23726604.
13. Jacobson PA, Oetting WS, Brearley AM, Leduc R, Guan W, Schladt D, Matas AJ, Lamba V, Julian BA, Mannon RB, Israni A. Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium. Transplantation 2011, 91:300-308. 3579501, 21206424.
14. Kolonko A, Chudek J, Wiecek A. Improved kidney graft function after conversion from twice daily tacrolimus to a once daily prolonged-release formulation. Transplant Proc 2011, 43:2950-2953. 10.1016/j.transproceed.2011.07.014, 21996198.
15. Tinti F, Meçule A, Poli L, Bachetoni A, Umbro I, Brunini F, Barile M, Nofroni I, Berloco PB, Mitterhofer AP. Improvement of graft function after conversion to once daily tacrolimus of stable kidney transplant patients. Transpl Proc 2010, 42:4047.
16. Guirado L, Cantarell C, Franco A, Huertas EG, Fructuoso AS, Fernandez A, Gentil MA, Rodriguez A, Paul J, Torregrossa JV. Efficacy and safety of conversion from twice-daily to once-daily tacrolimus in a large cohort of stable kidney transplant recipients. Am J Transplant 2011, 11:1965-1971. 10.1111/j.1600-6143.2011.03571.x, 21668633.
17. Zaltzman JS. A comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily cyclosporine on renal function in healthy volunteers. Transplantation 2010, 90:1185-1191.